The short-term impact of Botox injections on speech disability in adductor spasmodic dysphonia
Ferens Unit, Middlesex Hospital Outpatients Department, London, UK.Disability and Rehabilitation (Impact Factor: 1.99). 02/1997; 19(1):20-5. DOI: 10.3109/09638289709166441
This study investigates the impact of Botox injections on speech disability in a group of patients with adductor spasmodic dysphonia. Patient-perceived disability was assessed on the Speech Disability Questionnaire. A factor analysis on speech disability yielded five factors. Four of these, social isolation (p < 0.001), negative communication (p < 0.005), public avoidance (p < 0.05) and limited understanding (p < 0.01), showed significant change from prior to and one week post injection. Speech and language therapists' assessment also showed changes in voice quality over the same period. These findings are discussed in terms of the relationship between voice quality, disability and handicap, in adductor spasmodic dysphonia.
Article: Management of neurologic dysphonia[Show abstract] [Hide abstract]
ABSTRACT: Neurologic voice disorders are complex in nature. Successful treatment of these patients often relies on a combination of behavioral, pharmacologic, and surgical therapies to achieve the best possible voice outcome. This paper surveys the most current literature relating to the management of neurologic dysphonias. The topics selected for discussion have received the most attention across the disciplines of otolaryngology, neurology, and speech-language pathology, and represent those neurogenic voice disorders that have been the focus of basic and applied research in the past year.Current Opinion in Otolaryngology & Head and Neck Surgery 12/1998; 6(6):401-406. DOI:10.1097/00020840-199812000-00009 · 1.84 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: This systematic review of the literature addresses the medical management of spasmodic dysphonia (SD) and some related conditions. It was carried as part of the development of practice guidelines for the Academy of Neurologic Communication Disorders and Sciences (ANCDS). A search of electronic databases (PsychlNFO, MEDLINE, and CINAHL) and hand searches of relevant edited hooks yielded 103 intervention studies in the categories of recurrent laryngeal nerve (RLN) section (20 references), the use of botulinum toxin (Botox) injections for the management of SD (58 references), and miscellaneous interventions (25 references). It suggests that RLN section as a treatment for adductor SD results in a substantial degree of improvement for a substantial percentage of patients, but that recurrence of SD signs and symptoms is common. Botox injection also results in a substantial degree of improvement for a substantial percentage of patients. Benefits generally last for 3 to 4 months, but reinjection is required to maintain the effect. The side effects of a weak or breathy voice and mild dysphagia last for several weeks in many patients. The effectiveness of Botox injection for abductor SD is less pronounced and occurs in a smaller percentage of patients than adductor SD. (PsycINFO Database Record (c) 2012 APA, all rights reserved)Journal of medical speech-language pathology 11/2003; 11(4):ix-lviii. · 0.18 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: This review systematically examines the effects of botulinum toxin type A (BTX-A) on patient-reported outcomes across disorders using evidence-based criteria. The evidence provided by these studies ranged from randomized, controlled trials to case series. The effects of BTX-A on quality of life or global treatment outcomes were assessed in 48 studies across 16 different conditions. All but 7 of these reported benefits of BTX-A over baseline or the comparator condition (placebo or other treatment). The effects of BTX-A on impairment, activities, or participation were assessed in 46 studies across 17 different conditions. All but 4 reported benefits of BTX-A over baseline or the comparison group. The effects of BTX-A on satisfaction or preference were assessed in 14 studies across 11 different conditions, all of which reported high rates of satisfaction with BTX-A or preference over the comparator. These studies provide evidence that BTX-A exerts meaningful benefits on the quality of life of patients treated with this biologic agent.Clinical Neuropharmacology 09/2004; 27(5):234-44. DOI:10.1097/01.wnf.0000145508.84389.87 · 2.01 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.